- Trials with a EudraCT protocol (44,346)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,346 result(s) found.
Displaying page 1,530 of 2,218.
EudraCT Number: 2013-000189-12 | Sponsor Protocol Number: ABR43234 | Start Date*: 2013-03-14 |
Sponsor Name:University Medical Centre Nijmegen | ||
Full Title: Effects of the selective mineralocorticoid receptor antagonist eplerenone on extracellular formation of adenosine | ||
Medical condition: healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001421-27 | Sponsor Protocol Number: CA180-406 | Start Date*: 2013-09-18 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE | |||||||||||||
Medical condition: Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) with stable Complete Molecular Response (CMR) who have received dasatinib as first or second-line treatment for a minimum of 2 years at... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) ES (Ongoing) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002413-22 | Sponsor Protocol Number: Be-OnE1/08-03-2016 | Start Date*: 2016-10-31 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: Open label, Randomized (1:1), clinical trial to evaluate switching from dual regimens based on Dolutegravir plus a reverse transcriptase inhibitor to elvitegravir/cobicistat/emtricitabine/tenofovi... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001823-26 | Sponsor Protocol Number: IDECASRCT | Start Date*: 2017-12-12 | |||||||||||
Sponsor Name:UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA | |||||||||||||
Full Title: Efficacy and Safety of Intravenous Ferric Carboxymaltose in Patients Undergoing Cardiac Surgery A Randomized Controlled Study | |||||||||||||
Medical condition: Iron deficiency in cardiac surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002944-26 | Sponsor Protocol Number: DDD19DASA | Start Date*: 2020-01-24 |
Sponsor Name:KU Leuven Drug Delivery & Disposition | ||
Full Title: Exploring the gastrointestinal behavior of dasatinib in healthy volunteers | ||
Medical condition: Healthy human male volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-003556-31 | Sponsor Protocol Number: SHP-607-201 | Start Date*: 2015-02-10 |
Sponsor Name:Premacure AB, A Member of the Shire Group of Companies | ||
Full Title: Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care | ||
Medical condition: Retinopathy of Prematurity (ROP) | ||
Disease: | ||
Population Age: Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-003621-21 | Sponsor Protocol Number: TAK-771-3005 | Start Date*: 2022-12-06 | |||||||||||
Sponsor Name:Takeda | |||||||||||||
Full Title: A Phase 3, Open-label, Non-controlled, Extension Study to Evaluate the Long-term Safety of TAK-771 in Japanese Patients with Primary Immunodeficiency Disease (PID) | |||||||||||||
Medical condition: Primary Immunodeficiency Disease (PID) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004714-41 | Sponsor Protocol Number: GBG69 | Start Date*: 2012-05-18 | |||||||||||
Sponsor Name:GBG Forschungs GmbH | |||||||||||||
Full Title: A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto) | |||||||||||||
Medical condition: Patients with primary breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001015-32 | Sponsor Protocol Number: AGO-OVAR17 | Start Date*: 2011-11-15 | |||||||||||
Sponsor Name:AGO Research GmbH | |||||||||||||
Full Title: A prospective randomised Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian,... | |||||||||||||
Medical condition: Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary per... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) FI (Completed) NO (Completed) DK (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012797-12 | Sponsor Protocol Number: ACCORD 20/0904 - Prodige 17 | Start Date*: 2010-08-27 | |||||||||||
Sponsor Name:Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) | |||||||||||||
Full Title: Essai de phase II randomisé multicentrique évaluant l’efficacité d’une chimiothérapie seule ou combinée à l’AMG 102 ou au panitumumab en traitement de première ligne chez des patients atteints d’ad... | |||||||||||||
Medical condition: Adénocarcinome œsogastrique localement avancé (non résécable) ou métastatique | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003813-92 | Sponsor Protocol Number: EPT02/2016 | Start Date*: 2017-01-25 | |||||||||||
Sponsor Name:IBSA FARMACEUTICI ITALIA SRL | |||||||||||||
Full Title: Open clinical trial to evaluate the efficacy of intravesical instillation of hyaluronate added to early instillation of mitomycin vs early instillation of mitomycin in patients suffering from low r... | |||||||||||||
Medical condition: Low risk not muscle-infiltrating bladder neoplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001083-11 | Sponsor Protocol Number: LAL2116 | Start Date*: 2016-11-05 | |||||||||||
Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | |||||||||||||
Full Title: D-ALBA Front-Line Sequential Treatment of Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients with Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab | |||||||||||||
Medical condition: Acute Lymphoblastic Leukemia Philadelphia Chromosome Positive (Ph+) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002194-18 | Sponsor Protocol Number: CA209-9P9 | Start Date*: 2018-03-15 | ||||||||||||||||
Sponsor Name:Medical Center - University of Freiburg | ||||||||||||||||||
Full Title: Phase 1/2 Trial to determine the Response Rate of Nivolumab in Acute Myeloid Leukemia (AML) relapse after Allogeneic Hematopoietic Cell Transplantation (allo-HCT) | ||||||||||||||||||
Medical condition: Acute myeloid leukemia relapse after allo-HCT | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005817-61 | Sponsor Protocol Number: iVAC-CLL01 | Start Date*: 2016-07-28 | |||||||||||
Sponsor Name:University Hospital Tuebingen | |||||||||||||
Full Title: iVAC-CLL01: Patient-individualized peptide vaccination after first line therapy of CLL | |||||||||||||
Medical condition: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) after first line therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000127-12 | Sponsor Protocol Number: TM006 | Start Date*: 2022-01-03 | |||||||||||
Sponsor Name:Saniona A/S | |||||||||||||
Full Title: A Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi center, 16-week Dose finding, Safety and Efficacy Study with Open-label Extension Period of Tesomet in Adult and Adolescent Subjects ... | |||||||||||||
Medical condition: Prader-Willi Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001767-86 | Sponsor Protocol Number: COVIRL-002 | Start Date*: 2020-06-25 | |||||||||||
Sponsor Name:University College Dublin | |||||||||||||
Full Title: An open-label, multi-centre, randomised trial comparing different doses of single-dose tocilizumab in adults with severe, non-critical, PCR-confirmed COVID-19 infection with evidence of progressive... | |||||||||||||
Medical condition: COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005526-17 | Sponsor Protocol Number: 417-201-00012 | Start Date*: 2022-12-09 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development and Commercialization, Inc. | |||||||||||||
Full Title: A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy | |||||||||||||
Medical condition: Immunoglobulin A Nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005887-24 | Sponsor Protocol Number: GEMCAD-2103//MO44170 | Start Date*: 2022-11-25 | |||||||||||
Sponsor Name:Grupo Español Multidisciplinar de Cáncer Digestivo (GEMCAD) | |||||||||||||
Full Title: Phase II study of Atezolizumab plus Tiraglolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal | |||||||||||||
Medical condition: Locallized squamous cell carcinoma of the anal canal in the first-line setting. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002331-34 | Sponsor Protocol Number: ALOFEC-2019 | Start Date*: 2022-11-08 | |||||||||||
Sponsor Name:FIMABIS | |||||||||||||
Full Title: A multicenter, randomized, double-blind Phase IIb study to evaluate the safety and efficacy of the intralesional administration of two doses of expanded allogeneic adipose tissue adult stem mesench... | |||||||||||||
Medical condition: Fecal incontinence | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000501-36 | Sponsor Protocol Number: BAY63-2521/18694 | Start Date*: 2016-06-09 | |||||||||||
Sponsor Name:Bayer HealthCare | |||||||||||||
Full Title: An open-label, multi-national, multi-center, single-arm, uncontrolled, long-term extension study of orally administered riociguat in patients with symptomatic pulmonary arterial hypertension (PAH) ... | |||||||||||||
Medical condition: Hypertension, Pulmonary | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
